欧美久久呦网站,亚洲精品人妻在线播放

Pfizer Q3 2024: Oncology Business Grows 31%, Raises Full-Year Revenue Guidance Financial statements Pfizer's Q3 2024 report shows operating revenue rose 32% to $17.7 billion, with total revenue for the year so far at $45.9 billion. The oncology business grew 31%, driven by Talzenna and Padcev. Pfizer raised its full-year guidance to $61-64 billion.
Pfizer RSV Vaccine Approval Pfizer Pfizer's RSV vaccine, Abrysvo, has received FDA approval for use in high-risk adults aged 18-59, expanding its reach beyond older adults and pregnant women. This decision follows a successful Phase III trial, promising enhanced protection against respiratory syncytial virus (RSV) infections.
Pfizer's RSV Vaccine Shows 90% Efficacy Against Severe Respiratory Diseases Pfizer Pfizer's RSV vaccine, Abrysvo, shows 90% efficacy against severe respiratory illness in older adults, highlighting its potential as RSV cases rise. Despite CDC's narrower vaccination guidelines, Abrysvo remains a key product, nearing $1 billion in sales within seven months of FDA approval.
Victory! FDA Approves Pfizer's Hemophilia A or B Antibody Drug Marstacimab Pfizer FDA approves Pfizer’s new hemophilia drug, marstacimab (Hympavzi), for preventing bleeding episodes in patients with hemophilia A or B. The once-weekly therapy, priced at $795,600 per year, offers moderate improvements and aims to capture market share through its convenience.
Pfizer Q2 2024: 14% Growth in Non-COVID Products, Raises Full-Year Revenue Guidance Financial statements Pfizer reports a 2% revenue increase in Q2 2024, driven by 14% growth in non-COVID products like Seagen and Vyndaqel. Full-year revenue guidance raised to $59.5-$62.5 billion, with adjusted EPS guidance increased to $2.45-$2.65.
The most challenging field in innovative drugs: The 'Battle of the Gods' begins Novo Nordisk Explore the fierce competition in the weight-loss drug market as giants like Novo Nordisk, Eli Lilly, and Pfizer battle it out. With Novartis stepping back, innovation and market dynamics are put to the test.
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine Pfizer Discover Pfizer and BioNTech's milestone: CHMP recommends COMIRNATY? JN.1 vaccine for COVID-19, targeting Omicron JN.1 variant. Learn about enhanced efficacy, regulatory filings, and global distribution plans.

< Pre 1 23Next>

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水